G 
Guangzhou Baiyunshan Pharmaceutical Holdings Co 600332.SS · CNY
Health Care · Shanghai · 🇨🇳 China
19.91
-0.90%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥77.45bn
FY2016FY2025
Net income
CN¥2.98bn
FY2016FY2025
Free cash flow
−CN¥979.7m
FY2016FY2025
Shareholders' equity
CN¥37.79bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥77.45bn | CN¥74.99bn | CN¥75.52bn | CN¥70.79bn | CN¥69.01bn | CN¥61.67bn | CN¥64.95bn | CN¥42.23bn | CN¥20.95bn | CN¥20.04bn |
| Research and development | CN¥607.6m | CN¥763.8m | CN¥782.1m | CN¥819.5m | CN¥874.7m | CN¥611.9m | CN¥576.5m | CN¥585.5m | CN¥373.3m | CN¥330.4m |
| Operating income | CN¥3.39bn | CN¥3.47bn | CN¥5.12bn | CN¥5.07bn | CN¥4.79bn | CN¥3.03bn | CN¥3.52bn | CN¥3.84bn | CN¥2.46bn | CN¥1.47bn |
| Net income | CN¥2.98bn | CN¥2.84bn | CN¥4.06bn | CN¥3.97bn | CN¥3.72bn | CN¥2.92bn | CN¥3.19bn | CN¥3.44bn | CN¥2.06bn | CN¥1.51bn |
| Diluted earnings per share | 1.83 | 1.74 | 2.49 | 2.44 | 2.29 | 1.80 | 2.01 | 2.14 | 1.26 | 1.14 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥84.51bn | CN¥81.68bn | CN¥78.59bn | CN¥74.67bn | CN¥66.12bn | CN¥59.76bn | CN¥56.89bn | CN¥51.48bn | CN¥28.31bn | CN¥25.90bn |
| Cash and short-term investments | CN¥23.80bn | CN¥22.72bn | CN¥22.04bn | CN¥22.56bn | CN¥22.38bn | CN¥19.47bn | CN¥18.47bn | CN¥16.11bn | CN¥11.70bn | CN¥13.10bn |
| Total liabilities | CN¥43.39bn | CN¥43.91bn | CN¥41.91bn | CN¥41.03bn | CN¥34.79bn | CN¥31.55bn | CN¥30.90bn | CN¥28.34bn | CN¥9.05bn | CN¥8.24bn |
| Debt | — | CN¥13.94bn | CN¥11.97bn | CN¥12.06bn | CN¥13.40bn | CN¥12.85bn | CN¥10.63bn | CN¥9.29bn | CN¥295.0m | CN¥380.0m |
| Shareholders' equity | CN¥37.79bn | CN¥35.90bn | CN¥34.92bn | CN¥32.07bn | CN¥29.06bn | CN¥26.14bn | CN¥24.18bn | CN¥21.68bn | CN¥18.87bn | CN¥17.35bn |
| Shares outstanding | 1,626m | 1,626m | 1,626m | 1,626m | 1,626m | 1,624m | 1,590m | 1,608m | 1,638m | 1,321m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥260.2m | CN¥3.44bn | CN¥4.10bn | CN¥7.00bn | CN¥5.67bn | CN¥585.2m | CN¥5.02bn | CN¥5.22bn | CN¥1.83bn | CN¥2.44bn |
| Capital spending | −CN¥1.24bn | −CN¥1.13bn | −CN¥1.63bn | −CN¥1.38bn | −CN¥1.25bn | −CN¥876.5m | −CN¥2.40bn | −CN¥478.6m | −CN¥196.8m | −CN¥228.0m |
| Free cash flow | −CN¥979.7m | CN¥2.31bn | CN¥2.48bn | CN¥5.62bn | CN¥4.42bn | −CN¥291.3m | CN¥2.62bn | CN¥4.74bn | CN¥1.64bn | CN¥2.22bn |
| Dividends paid | −CN¥1.30bn | −CN¥2.25bn | −CN¥1.19bn | −CN¥1.12bn | −CN¥874.7m | −CN¥957.6m | −CN¥689.3m | −CN¥870.6m | −CN¥463.6m | −CN¥512.5m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥18.81bn | CN¥23.28bn | CN¥16.05bn | CN¥19.77bn | CN¥19.36bn | CN¥22.47bn | CN¥15.93bn | CN¥18.02bn |
| Operating income | CN¥464.5m | CN¥2.26bn | −CN¥734.2m | CN¥1.02bn | CN¥720.1m | CN¥2.16bn | −CN¥404.7m | CN¥831.4m |
| Net income | CN¥312.2m | CN¥1.78bn | −CN¥326.9m | CN¥793.9m | CN¥694.8m | CN¥1.82bn | −CN¥323.5m | CN¥609.4m |
| Diluted earnings per share | 0.19 | 1.10 | -0.20 | 0.49 | 0.43 | 1.12 | -0.20 | 0.37 |
| Cash from operations | — | — | CN¥1.84bn | CN¥1.73bn | CN¥500.0m | −CN¥3.83bn | CN¥4.30bn | CN¥1.33bn |
| Capital spending | −CN¥295.0m | −CN¥224.0m | −CN¥330.0m | −CN¥412.0m | −CN¥270.0m | −CN¥226.0m | −CN¥316.0m | −CN¥247.0m |
| Free cash flow | — | — | CN¥1.51bn | CN¥1.32bn | CN¥230.0m | −CN¥4.06bn | CN¥3.99bn | CN¥1.08bn |
| Total assets | CN¥87.82bn | CN¥89.76bn | CN¥84.51bn | CN¥83.17bn | CN¥82.42bn | CN¥80.05bn | CN¥81.68bn | CN¥79.26bn |
| Cash and short-term investments | — | — | CN¥23.80bn | CN¥18.33bn | CN¥11.83bn | CN¥18.54bn | CN¥18.27bn | CN¥17.20bn |
| Debt | CN¥5.09bn | CN¥4.86bn | CN¥20.32bn | CN¥17.09bn | CN¥12.85bn | CN¥11.10bn | CN¥11.93bn | CN¥12.06bn |
| Shareholders' equity | CN¥39.13bn | CN¥39.56bn | CN¥37.79bn | CN¥37.91bn | CN¥37.76bn | CN¥37.72bn | CN¥35.90bn | CN¥36.22bn |
Financial ratios
Data as of 20 Sept 2026
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Operating margin | 4.4% | 4.6% | 6.8% | 7.2% | 6.9% | 4.9% |
| Net margin | 3.9% | 3.8% | 5.4% | 5.6% | 5.4% | 4.7% |
| Return on equity | 7.9% | 7.9% | 11.6% | 12.4% | 12.8% | 11.2% |
| Return on assets | 3.5% | 3.5% | 5.2% | 5.3% | 5.6% | 4.9% |
| Free cash flow yield | 4.8% | 14.5% | 18.2% | 26.6% | 22.0% | 4.6% |
| Revenue growth | 3.3% | -0.7% | 6.7% | 2.6% | 11.9% | -5.0% |
| Earnings growth | 5.2% | -30.1% | 2.2% | 6.6% | 27.6% | -8.6% |
| Current ratio | 1.57x | 1.48x | 1.55x | 1.53x | 1.64x | 1.62x |
| Debt to equity | 0.54x | 0.33x | 0.32x | 0.35x | 0.32x | 0.34x |
| Equity ratio | 44.7% | 44.0% | 44.4% | 42.9% | 44.0% | 43.7% |
| Interest coverage | 7.93x | 7.91x | 10.89x | 11.20x | 10.89x | 7.91x |
| R&D as a share of sales | 0.8% | 1.0% | 1.0% | 1.2% | 1.3% | 1.0% |
| Buybacks as a share of market value | 0.0% | -0.0% | 0.0% | 0.0% | -0.1% | -2.2% |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 3.0% | 4.7% | 15.0% |
| Operating income | -12.6% | 2.3% | 9.2% |
| Net income | -9.1% | 0.5% | 8.7% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Operating margin | 4.5% | 5.7% | 5.8% | 6.3% |
| Net margin | 3.8% | 4.6% | 4.8% | 5.4% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings | 14.0 | 16.3 | 11.5 | 12.2 | 14.9 | 16.3 | 17.8 | 16.7 | 25.5 | 21.0 |
| Price to sales | 0.5 | 0.6 | 0.6 | 0.7 | 0.8 | 0.8 | 0.9 | 1.4 | 2.5 | 1.6 |
Dividends and splits
Per share, in the currency the company pays
Paid for 12 years. Last went ex-dividend on 16 Jun 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Paid in the year | 0.45 | 0.80 | 1.149 | 0.732 | 0.687 | 0.538 | 0.589 | 0.424 |
- 1-to-1 reverse split · 24 Apr 2006
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.